Simplex Trading
TLIS

Simplex Trading’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Simplex Trading’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-53
Closed -$3K – 11631
2021
Q4 		$3K Buy
+53
New +$3.96K ﹤0.01% 9903

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading's TLIS Position: Q1 2023 in Review

Simplex Trading sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2023, closing a stake of 11 shares.

Simplex Trading first reported a position in TLIS in Q4 2021 and held it in 5 quarters. The position peaked at $4K in Q4 2021. 22 funds tracked by Wall St. Rank hold TLIS as of Q1 2023.

  • Simplex Trading reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2023 after selling out during the quarter.
  • Simplex Trading sold 11 Talis Biomedical Corporation Common Stock shares in Q1 2023.
  • Simplex Trading first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and held it in 5 quarters.
  • Simplex Trading's Talis Biomedical Corporation Common Stock position peaked at $4K in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2023.

Based on Simplex Trading's 13F filing for Q1 2023, filed 27 Apr 2023.